New lupus drug candidate enters human safety testing
NCT ID NCT07215663
First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 19 times
Summary
This study is testing a new medicine, cizutamig, in people with systemic lupus erythematosus (SLE). The main goal is to check if it is safe and how the body handles it. About 47 adults with active lupus who have not responded well enough to other treatments will take part. This is an early-stage trial, so it focuses on safety and dosing, not yet on curing the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese Academy of Medical Sciences and Peking Union Medical College Hospital
RECRUITINGBeijing, China
Conditions
Explore the condition pages connected to this study.